Skip to main content
main-content

Latest oncology news

23-01-2020 | Oncology | News | Article

Eating more vegetables does not reduce low-grade prostate cancer progression risk

A behavioral intervention to increase vegetable consumption does not reduce the risk for disease progression over 2 years in men with early-stage prostate cancer undergoing active surveillance, phase 3 study data show.

21-01-2020 | Oncology | News | Article

Age no bar for treatment selection in older NSCLC patients

Age should not be a selection factor for treatment decisions in older individuals with non-small-cell lung cancer, suggest two studies published in Cancer.

21-01-2020 | Oncology | News | Article

Apalutamide–ADT indication expanded in Europe

Read more on this EMA positive opinion here

20-01-2020 | Oncology | News | Article

First-line ramucirumab–erlotinib supported by EMA for metastatic NSCLC

Click through to find out more

20-01-2020 | Oncology | News | Article

Crizotinib active against NSCLC with MET exon 14 alterations

The multikinase inhibitor crizotinib elicits responses and is well tolerated in people with non-small-cell lung cancer positive for MET exon 14 mutations, shows the PROFILE 1001 trial.

17-01-2020 | Oncology | News | Article

Similar outcomes with neoadjuvant and concurrent sequencing of ADT, prostate RT

Biochemical relapse-free survival and overall survival rates are comparable in men with localized prostate cancer who start androgen-deprivation therapy before or at the same time as dose-escalated prostate radiotherapy, phase 3 study data show.

17-01-2020 | Oncology | News | Article

Performance status modulates survival benefit of ICIs in advanced urothelial cancer

A poor ECOG performance status negatively impacts overall survival in patients with advanced urothelial cancer taking immune checkpoint inhibitors, shows a real-world study.

16-01-2020 | Oncology | News | Article

PSA repeat screening strategy should be tailored to baseline PSA

Baseline prostate-specific antigen levels in men screened between the ages of 55 and 60 years are significantly associated with long-term risk for clinically significant prostate cancer, shows an analysis of data from the PLCO Cancer Screening Trial.

15-01-2020 | Oncology | News | Article

High BMI linked to improved survival with atezolizumab in advanced NSCLC patients

Being overweight or obese is associated with favorable survival outcomes in advanced non-small cell lung cancer patients treated with atezolizumab, research published in JAMA Oncology suggests.

15-01-2020 | Oncology | News | Article

Prostatectomy-associated urinary incontinence disparities persist at 5 years

Men with favorable- and unfavorable-risk prostate cancer who undergo prostatectomy report worse urinary incontinence at 5 years than men treated with other contemporary management options, US research shows.

13-01-2020 | Oncology | News | Article

Novel DNA damage repair mutations identified in mesothelioma

Germline pathogenic variants, primarily in DNA damage repair genes, are present in about 12% of patients with malignant pleural mesothelioma, report US researchers.

10-01-2020 | Oncology | News | Article

Pembrolizumab gains bladder cancer indication in USA

Read more about this decision here

10-01-2020 | Oncology | News | Article

Alcohol use high among cancer survivors

Over half of cancer survivors report being current drinkers, including about a fifth who appear to engage in excessive drinking behaviors, finds a US study.

09-01-2020 | Oncology | News | Article

Osimertinib a potential option for NSCLC with uncommon EGFR mutations

Individuals with advanced non-small-cell lung cancer harboring uncommon EGFR mutations have favorable outcomes in response to osimertinib treatment, say Korean researchers.

08-01-2020 | Oncology | News | Article

PD-1 inhibition may result in better solid tumor survival than PD-L1 inhibition

Treatment with PD-1 inhibitors offers better overall survival, with comparable tolerability, than does treatment with PD-L1 inhibitors for patients with solid tumors such as non-small-cell lung cancer, suggests a systematic review and meta-analysis.

07-01-2020 | Oncology | News | Article

Tumor microenvironment changes implicated in clear cell RCC obesity paradox

Tumors from obese patients with clear cell renal cell carcinoma have higher angiogenesis scores than those from normal-weight patients, as well as differences in the tumor microenvironment, US researchers report.

07-01-2020 | Oncology | News | Article

Single adjuvant chemotherapy cycle may be sufficient in testicular cancer

A single cycle of adjuvant bleomycin, etoposide, and cisplatin may be enough to reduce rates of malignant recurrence in men with high-risk, stage I, nonseminomatous or combined testicular germ cell tumors, suggests the 111 study.

03-01-2020 | Prostate cancer | News | Article

Pembrolizumab may be an option for treatment-refractory mCRPC

Pembrolizumab monotherapy shows activity against both RECIST-measurable and bone-predominant treatment-refractory metastatic castration-resistant prostate cancer, results of the KEYNOTE-199 phase 2 trial show.

02-01-2020 | Oncology | News | Article

Early promise with ganetespib not replicated in phase 3 lung adenocarcinoma trial

Adding the potent heat shock protein 90 inhibitor ganetespib to docetaxel does not improve survival among patients with advanced-stage lung adenocarcinoma when used in a second-line setting, results of the GALAXY-2 trial show.

20-12-2019 | Oncology | News | Article

Enzalutamide, enfortumab vedotin-ejfv receive FDA nods

Click here for more information

Image Credits